Precigen, Inc. (NASDAQ:PGEN - Free Report) - Stock analysts at HC Wainwright decreased their FY2026 EPS estimates for Precigen in a research report issued to clients and investors on Friday, November 15th. HC Wainwright analyst S. Ramakanth now anticipates that the biotechnology company will earn $0.01 per share for the year, down from their previous forecast of $0.02. HC Wainwright has a "Buy" rating and a $4.00 price target on the stock. The consensus estimate for Precigen's current full-year earnings is ($0.44) per share. HC Wainwright also issued estimates for Precigen's FY2027 earnings at $0.22 EPS and FY2028 earnings at $0.39 EPS.
Other equities research analysts have also recently issued reports about the stock. JMP Securities decreased their price target on shares of Precigen from $14.00 to $7.00 and set a "market outperform" rating on the stock in a research note on Thursday, August 15th. StockNews.com upgraded shares of Precigen to a "sell" rating in a report on Thursday, August 1st. Two research analysts have rated the stock with a sell rating and four have assigned a buy rating to the company. According to data from MarketBeat, Precigen currently has a consensus rating of "Hold" and an average target price of $7.00.
Read Our Latest Report on Precigen
Precigen Price Performance
PGEN traded down $0.03 during trading on Monday, reaching $0.79. 1,087,496 shares of the stock were exchanged, compared to its average volume of 955,472. The business's 50 day moving average price is $0.92 and its two-hundred day moving average price is $1.24. Precigen has a 1 year low of $0.78 and a 1 year high of $1.93. The company has a market capitalization of $232.01 million, a price-to-earnings ratio of -1.44 and a beta of 1.68.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the business. Traphagen Investment Advisors LLC purchased a new position in shares of Precigen in the 3rd quarter valued at $29,000. Stifel Financial Corp lifted its stake in shares of Precigen by 94.9% during the third quarter. Stifel Financial Corp now owns 32,200 shares of the biotechnology company's stock worth $30,000 after purchasing an additional 15,680 shares in the last quarter. EntryPoint Capital LLC purchased a new stake in shares of Precigen in the first quarter worth about $31,000. SG Americas Securities LLC grew its stake in shares of Precigen by 44.2% in the third quarter. SG Americas Securities LLC now owns 45,063 shares of the biotechnology company's stock valued at $43,000 after buying an additional 13,823 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its holdings in shares of Precigen by 86.6% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 55,337 shares of the biotechnology company's stock valued at $52,000 after buying an additional 25,681 shares during the period. 33.51% of the stock is owned by institutional investors and hedge funds.
Precigen Company Profile
(
Get Free Report)
Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.
See Also
Before you consider Precigen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Precigen wasn't on the list.
While Precigen currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Like this article? Share it with a colleague.
Link copied to clipboard.
